Development of cancer treatment that attacks the protein that causes the disease carefully

Researchers at the New York University Cancer Center have developed a new treatment based on the development of the first targeted molecules of cancer proteins, using protein engineering techniques. The results of the research published in Nature Chemical Biology magazine showed the ability to target the HER2 -infected protein, which causes different types of cancer without affecting the natural protein found in healthy cells. Her2 -protein is a future on the surface of many cells, especially brush cells. A new treatment for cancer and HER2 protein plays an important role in cell growth and reproduction, and if a boom occurs in this protein, or an increase in the version, it can lead to an uncontrolled growth of cells, causing certain types of cancer, such as breast cancer. For this reason, the HER2 protein is an important target for the targeted cancer treatments, as these treatments seek to impede the activity of this protein, or to prevent its interaction with other molecules that stimulate the growth of cancer cells. The researchers say that one of the most important challenges of the HER2 proteins that causes cancer is the great similarity between the converted version and the natural version of the protein, which makes the motivated protein without damaging healthy cells, which is complicated, which the research team has overcome this time. The research team, led by Dr. Shuhai Kodi, a professor in the Department of Biochemistry and Molecular Pharmacology at the University of New York, has managed to develop an anti -body that can accurately distinguish between the circulating and natural version of the HER2 protein. “Our goal was to make an anti -body that could learn about one difference in 600 amino acids, which is considered a major challenge, but success in discovering this difference with great accuracy was a surprise to us.” The cause of cancer HER2, found on the roofs of many cells, plays an important role in activating signs that control cell growth. And when a mutation occurs in one amino acid in this protein, it is always transformed into an active position, leading to uncontrolled cell division, and thus cancer. Cancer can also occur if there are excessive copies of the HER2 production, increasing protein levels on the surface of the cells. The treatments currently available, such as “Trastiosomab” and “Bertrozomab”, are aimed at the protein on the surface of the cells, but it cannot distinguish between the conversation and the natural version of HER2, which increases the possibility of negative and dangerous effect on healthy cells. Protein engineering techniques, but the new system developed by researchers depends on the use of protein engineering techniques to develop antibodies that can target only the motivated version of protein. Researchers have developed antibodies using developmental techniques similar to the development of natural antibodies, as these antibodies have undergone various rounds of modification and selection to discover the variables that HER2 can only target without normal. The team was able to get photos using an electronic microscope, which helped them to constantly improve the antibody designs. The selective identification of the HER2 conversation was not just enough to develop an effective treatment, as antibodies must work with the immune system to eliminate cancer cells. The biggest challenge was the presence of some HER2 molecules around the surface of cancer cells, reducing the effectiveness of antibodies in the target cells. To counteract this challenge, researchers turned the antibody into a double -bound molecule with immune -to -cells, and the targeted anti -her2 -body was combined with another anti -immune body, and this molecule connected the anti -Anti -body to the cancerous cell, while the other she stimulated the TT -cell. The elimination of cancer cells and preliminary tests showed that this method succeeded in eliminating the cancer cells containing HER2 axis in the laboratory without affecting the normal cells. And when molecules were tested in mice containing crops containing HER2, the results showed a significant reduction in the size of the crops, without any significant side effects on mice, such as weight loss or visible pathological symptoms. Although the preliminary results are promising, the researchers indicate that more studies are needed to develop this treatment and make it available for clinical use, as the team plans to apply the same technology to other motivated proteins that cause cancer.